Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr

Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023

Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group

The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions

Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole

Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America

Cipla EU to form JV in USA

Cipla to further invest Rs. 42 crore in GoApptiv

Expands patient reach to remotest towns by furthering investment in GoApptiv

Cipla partners with TEACH to create career opportunities for hearing-impaired youth

The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals

Cipla launches drone delivery of critical medicines in Himachal Pradesh

Commenced operations in flood-affected Himachal Pradesh

Cipla Medpro South Africa to acquire Actor Pharma

This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market

Cipla launches knowledge sharing platform ‘Ciplamed 2.0’

CiplaMed 2.0 leverages advanced analytics and automation

Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr

Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023